mRNA Vaccine Market Size & Share Report, 2032

mRNA Vaccine Market - By Type (Self-Amplifying mRNA Vaccines, Conventional Non-Amplifying mRNA Vaccines), End-use (Hospitals & Clinics, Research Laboratories) & Forecast 2023 - 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; mRNA vaccineindustry 360&ordm; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Type trends

2.1.4&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;mRNA Vaccine Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of chronic and infectious disease

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing focus on preventive healthcare

3.2.1.3&nbsp;&nbsp;&nbsp;Growing R&amp;D investments for developing mRNA based vaccines

3.2.1.4&nbsp;&nbsp;&nbsp;Increasing government initiatives and policies to promote vaccination

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High price associated with mRNA-based vaccines

3.2.2.2&nbsp;&nbsp;&nbsp;Stringent regulations for the approval of mRNA vaccine

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By type

3.3.2&nbsp;&nbsp;&nbsp; By end-use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.6&nbsp;&nbsp;&nbsp; Future potential

3.7&nbsp;&nbsp;&nbsp; Pipeline analysis

3.8&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

4.6&nbsp;&nbsp;&nbsp; Strategy outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;mRNA Vaccine Market Size and Forecast, By Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by type

5.2&nbsp;&nbsp;&nbsp; Self-amplifying mRNA vaccines

5.3&nbsp;&nbsp;&nbsp; Conventional non-amplifying mRNA vaccines

Chapter 6&nbsp;&nbsp;&nbsp;mRNA vaccine Market Size and Forecast, By End-use (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

6.2&nbsp;&nbsp;&nbsp; Hospitals &amp; clinics

6.3&nbsp;&nbsp;&nbsp; Research laboratories

6.4&nbsp;&nbsp;&nbsp; Other end-uses

Chapter 7&nbsp;&nbsp;&nbsp;mRNA vaccine Market Size and Forecast, By Region (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by region

7.2&nbsp;&nbsp;&nbsp; North America

7.2.1&nbsp;&nbsp;&nbsp; U.S.

7.2.2&nbsp;&nbsp;&nbsp; Canada

7.3&nbsp;&nbsp;&nbsp; Europe

7.3.1&nbsp;&nbsp;&nbsp; Germany

7.3.2&nbsp;&nbsp;&nbsp; UK

7.3.3&nbsp;&nbsp;&nbsp; France

7.3.4&nbsp;&nbsp;&nbsp; Spain

7.3.5&nbsp;&nbsp;&nbsp; Italy

7.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

7.4&nbsp;&nbsp;&nbsp; Asia Pacific

7.4.1&nbsp;&nbsp;&nbsp; Japan

7.4.2&nbsp;&nbsp;&nbsp; China

7.4.3&nbsp;&nbsp;&nbsp; India

7.4.4&nbsp;&nbsp;&nbsp; Australia

7.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

7.5&nbsp;&nbsp;&nbsp; Latin America

7.5.1&nbsp;&nbsp;&nbsp; Brazil

7.5.2&nbsp;&nbsp;&nbsp; Mexico

7.5.3&nbsp;&nbsp;&nbsp; Argentina

7.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

7.6&nbsp;&nbsp;&nbsp; MEA

7.6.1&nbsp;&nbsp;&nbsp; South Africa

7.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

7.6.3&nbsp;&nbsp;&nbsp; Rest of MEA

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; Pfizer Inc.

8.2&nbsp;&nbsp;&nbsp; Moderna, Inc.

8.3&nbsp;&nbsp;&nbsp; BioNTech SE

8.4&nbsp;&nbsp;&nbsp; GlaxoSmithKline

8.5&nbsp;&nbsp;&nbsp; Daiichi Sankyo

8.6&nbsp;&nbsp;&nbsp; Ethris GmbH

8.7&nbsp;&nbsp;&nbsp; AIM Vaccine

8.8&nbsp;&nbsp;&nbsp; Arcturus Therapeutics Inc.

8.9&nbsp;&nbsp;&nbsp; CureVac

8.10&nbsp;&nbsp;&nbsp; AstraZeneca

8.11&nbsp;&nbsp;&nbsp; Sanofi

&nbsp;&nbsp;&nbsp;

mRNA Vaccine Market

Get a free sample of this report